ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering"), resulting in gross proceeds of $10.0 million, assuming none of the accompanying Common Warrants issued in the Offering are exercised.

The shares of common stock (or pre-funded warrants) and the accompanying Common Warrants were issued separately but purchased together in this Offering. The combined public offering price for each share of common stock and accompanying Common Warrant was $0.43, and the combined offering price for each pre-funded warrant and accompanying Common Warrant was $0.429, which equals the public offering price per share of the common stock and accompanying Common Warrant, less the $0.001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the Offering were $10.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Aytu.

The pre-funded warrants were exercised in full on August 11, 2022. Total shares outstanding after the Offering, including the exercise of the pre-funded warrants, was 62,432,727. All securities sold in the Offering were sold by the Company.

The Company intends to use the net proceeds from the Offering for advancing the development of its pipeline assets, including for advancing the PREVEnt Trial evaluating AR101 for the treatment of vascular Ehlers-Danlos Syndrome (VEDS), for growth of the Company's commercial business, and for working capital and general corporate purposes.

Cantor and Canaccord Genuity acted as the joint bookrunners for the Offering.

Copies of the prospectus supplement and the accompanying prospectus relating to and describing this Offering may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, NY 10022, or by email at prospectus@cantor.com or by contacting Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110 or by email at prospectus@cgf.com. These documents may also be obtained for free on the SEC's website located at http://www.sec.gov.

There is no established public trading market for the Common Warrants, and the Company does not expect a market to develop. Additionally, the Company does not intend to apply for the Common Warrants on any national securities exchange or other nationally recognized trading system.

Aytu is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The Company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes AR101 (enzastaurin), a PKCβ inhibitor in development for the treatment of vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. AR101 has received Orphan Drug designation from the U.S. Food and Drug Administration and the European Medicines Agency. Aytu is also researching and advancing the development of the Healight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential application in the treatment of severe, difficult-to-treat respiratory infections.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "might," "plans," "predicts," "projects," "should," "targets," "will," or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the expected uses of the proceeds from the Offering You are cautioned not to place undue reliance on any forward-looking statements made by Aytu's management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Aytu does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

Mark Oki Chief Financial Officer moki@aytubio.com

Robert Blum Lytham Partners blum@lythampartners.com

View source version on accesswire.com: https://www.accesswire.com/712083/Aytu-BioPharma-Announces-Closing-of-100-Million-Registered-Public-Offering

In this article, we will discuss some of the best stocks to buy according to Dave Smith, Chief Investment Officer at investment management company Rockland Trust. If you want to explore similar stocks, you can also look at Long-Term Analyst: Buy These 5 Stocks. David Smith has been in the financial services industry for over […]

Aurora Cannabis, Canopy Growth, OrganiGram Holdings, and Tilray Brands are all in the red yet again today.

Electric vehicle (EV) charging network company ChargePoint Holdings (NYSE: CHPT) gave investors a mixed fiscal 2023 second-quarter earnings report earlier this week. ChargePoint exceeded the high end of its prior guidance for revenue. The company had told investors to expect revenue of between $96 million and $106 million for the period, and it achieved $108.3 million in sales.

Chinese stocks have come under pressure for various reasons over the past year and a half or so; a slowing economy has been one cause while domestic tussles with the regulators haven’t helped either, particularly for those in the tech sector. Another element keeping sentiment low and impacting performance has been the fear of de-listing for U.S.-listed Chinese stocks. This is on account of Chinese companies not meeting U.S. auditing standards. But the prospects of de-listing might be less likely

Follow Buffett’s lead. And collect big dividends too.

(Reuters) -Private equity firm Oak Street Real Estate Capital LLC has made an offer to acquire as much as $2 billion of property from Kohl's Corp and have the U.S. retailer lease back its stores, according to people familiar with the matter. Oak Street's interest offers Kohl's another chance to cut a deal after negotiations to sell itself to Franchise Group Inc, owner of the Vitamin Shoppe, for almost $8 billion fell through in July over the department store operator's deteriorating business prospects. Oak Street had sought to help finance Franchise Group's bid.

Fast-growing cybersecurity company CrowdStrike (NASDAQ: CRWD) reported strong fiscal second-quarter results earlier this week. Its fiscal second-quarter revenue and adjusted earnings per share both came in higher than analysts' consensus forecasts, as annual recurring revenue soared 59% year over year, surpassing $2 billion for the first time. While it's true that CrowdStrike's business has been firing on all cylinders, there has been significant pressure on growth stocks in 2022 as investors appear to be more sensitive to valuation risk.

Investors need to pay close attention to Upstart (UPST) stock based on the movements in the options market lately.

Cathie Wood's ARK Invest cut its stake in Nvidia ahead of the graphic chipmaker's results last month. Now it's snapped up the stock which has dropped to a 52-week low.

Recently, Zacks.com users have been paying close attention to Energy Transfer LP (ET). This makes it worthwhile to examine what the stock has in store.

The S&P 500 broke below 4,000 this week, for the first time since the end of July. It has investors wondering: Does this mark the low point of a roller coaster ride? Stocks rose all last year, fell from January to June, rallied from July to mid-August, and now are falling again. According to Wells Fargo strategist Paul Christopher, it’s evidence that the stock rally is sputtering to a halt. Christopher writes that “Cracks in financial market liquidity are appearing,” and says of the S&P 500, “3,

Ready to go bottom fishing again? Any good angler can tell you that there’s plenty of good eating just waiting at the bottom of the creek, or the pond, or the lake. The same concept also holds for stocks – investors can always find some quality equities down at the market bottoms. Stocks get down there for a multitude of reasons, and the reasons aren’t always related to any fundamental flaw in the company or its share trading policies. Sometimes, it’s some idiosyncratic business move, or over-re

Finally, investors have a good reason for why the U.S. stock market will suffer above-average volatility and below-average performance this month: It’s the Fed. Relatively few advisers are focusing on this outcome — at least among the more than 100 I regularly monitor.

Piper Sandler analyst Alexander Potter raised his price target on Tesla stock. He thinks shares could fall in coming weeks for three reasons.

U.S. stocks fell sharply on Friday, surrendering all of the gains from a post-jobs report rally ahead of the Labor Day holiday weekend.

SQM (SQM) could produce exceptional returns because of its solid growth attributes.

This has been one of the most trying years in decades for Wall Street. The benchmark S&P 500, which is typically viewed as a barometer of Wall Street's health, produced its worst first-half return since 1970. While things have certainly not gone Wall Street's way in 2022, the investing community has still managed to find a bright light amid a gloomy situation.

Exploration and production businesses are witnessing big gains from a healthy crude price trajectory. Thus, Diamondback (FANG), Pioneer (PXD) & Matador (MTDR) are poised to benefit.

Yahoo Finance's Ines Ferre joins the Live show to break down how stocks are moving in intraday trading.

A “superbubble” appears dangerously near its "final act" after the recent rally in U.S. stocks lured some investors back into the market just ahead of potential “tragedy,” according to Jeremy Grantham, the legendary co-founder of Boston-based investment firm GMO.